Dr. Taylor C. Bear, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 434
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Clvlnd Clinic Lerner College of Med of Case Wstn Rsv University
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MO license 2006022060
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Healthcare System, Inc Chattanooga, TN
- Affiliate of Vitruvian Health Cleveland, TN
- Rhea Medical Center Dayton, TN
Medical groups
- Bradley Physician Services, LLC (79 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 434
- Services billed
- 19,478
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, onabotulinumtoxina, 1 unit | 13,400 | 21 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 297 | 157 |
| Established patient office or other outpatient visit, 20-29 minutes | 111 | 101 |
| Nerve conduction, 5-6 studies | 79 | 79 |
| Established patient office or other outpatient visit, 10-19 minutes | 67 | 66 |
| Established patient office or other outpatient visit, 30-39 minutes | 66 | 62 |
| New patient office or other outpatient visit, 45-59 minutes | 63 | 63 |
| Nerve conduction, 9-10 studies | 53 | 53 |
| Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | 46 | 15 |
| Measurement of brain wave activity (eeg), awake and drowsy | 39 | 38 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Memantine Hcl Other prescribers in Cleveland, TN | 186 |
| Levetiracetam Other prescribers in Cleveland, TN | 179 |
| Gabapentin Other prescribers in Cleveland, TN | 159 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Cleveland, TN | 151 |
| Donepezil Hcl Other prescribers in Cleveland, TN | 142 |
| Primidone Other prescribers in Cleveland, TN | 113 |
| Lacosamide Other prescribers in Cleveland, TN | 73 |
| Botox (onabotulinumtoxina) | 72 |
| Topiramate Other prescribers in Cleveland, TN | 71 |
| Baclofen Other prescribers in Cleveland, TN | 62 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 38 companies reported 217 payments worth $10,671 in total to this clinician.
| Pfizer Inc. | $5,300 |
|---|---|
| Livanova USA, Inc. | $1,691 |
| AbbVie Inc. | $399 |
| Neurocrine Biosciences, Inc. | $300 |
| UCB, Inc. | $229 |
| Lundbeck LLC | $221 |
| Argenx US, Inc. | $219 |
| Biogen, Inc. | $211 |
| Consulting Fee | $5,000 |
|---|---|
| Food and Beverage | $4,466 |
| Travel and Lodging | $1,205 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 20, 2025 | Consulting Fee PANZYGA · IMMUNOLOGY;INFLAMMATION | $2,500 |
| Pfizer Inc. May 20, 2025 | Consulting Fee PANZYGA · IMMUNOLOGY;INFLAMMATION | $2,500 |
| Livanova USA, Inc. Sep 12, 2025 | Travel and Lodging VNS Therapy · Neurology · travel to Chicago, IL · in-kind | $471 |
| Livanova USA, Inc. Sep 12, 2025 | Travel and Lodging VNS Therapy · Neurology · travel to Chicago, IL · in-kind | $441 |
| Livanova USA, Inc. Sep 12, 2025 | Travel and Lodging VNS Therapy · Neurology · travel to Chicago, IL · in-kind | $292 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $38,547 in research payments for these studies, mostly to the institutions running them.
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. · Active, not recruiting · NCT06417775 - A phase 4 openlabel study to evaluate the safety and tolerability of daily dosing of rimegepant in episodic migraine prevention
Pfizer Inc. - M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06808984 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
AbbVie Inc. - Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor
AbbVie Inc. · Completed · NCT05216250
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.